Crossmark

Evaluation of neurofibromatosis type 1 progression using a nationwide registry of patients who submitted claims for medical expense subsidies in Japan between 2008 and 2012

Crossref DOI link: https://doi.org/10.1186/s13023-019-1148-8

Published Online: 2019-07-05

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamauchi, Takashi https://orcid.org/0000-0001-5295-4082
Suka, Machi

Nishigori, Chikako

Yanagisawa, Hiroyuki
Funding

Funding for this research was provided by:

Ministry of Health, Labour and Welfare (H29-nanchi-tou(nan)-ippan-021)
License Information

Text and Data Mining valid from 2019-07-05

Version of Record valid from 2019-07-05
More Information

Article History

Received: 17 December 2018

Accepted: 26 June 2019

First Online: 5 July 2019

Ethics approval and consent to participate

: We did not seek ethical approval for this study because it used a completely anonymous database of NF1 cases provided by the MHLW based on a legal foundation in Japan. The database did not include any personally identifiable information, such as names or addresses.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below